Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue

PHASE3TerminatedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

August 21, 2017

Primary Completion Date

January 14, 2019

Study Completion Date

April 23, 2019

Conditions
Mammographic Breast Density
Interventions
DRUG

4-OH tamoxifen

4-Hydroxytamoxifen (afimoxifene) gel

DRUG

Placebo

An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.

Trial Locations (19)

22903

University of Virginia Medical Park Northridge, Charlottesville

27713

Carolina Women's Research and Wellness Center, Durham

28009

Instituto Palacios Salud de La Mujer, Madrid

29464

Coastal Carolina Research Center, Inc., Mt. Pleasant

33180

South Florida Medical Research, Aventura

34239

Physician Care Clinical Research, LLC, Sarasota

34748

Lake OB-GYN Associates of Mid-Florida, Leesburg

43213

Aventiv Research, Inc., Columbus

60322

Private Practice - Gynecology, Frankfurt am Main

85209

Mesa Obstetricians and Gynecologists/Cactus Clinical Research, Mesa

85712

Visions Clinical Research, Tucson

87109

Bosque Women Care/Cactus Clinical Research, Albuquerque

89113

Affiliated Clinical Research, Inc., Las Vegas

90033

USC-Keck Medical Center, Los Angeles

90211

United Clinical Research, Beverly Hills

91010

City of Hope, Duarte

98004

Overlake Internal Medicine Associates, PS, Bellevue

98372

Dedicated Women's Health Specialists, Puyallup

08536

Center for Women's Health and Wellness, Plainsboro

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BHR Pharma, LLC

INDUSTRY